Quarterlies round-up: AngioDynamics ends year on sales and earnings high
This article was originally published in Clinica
A strong 56% increase in domestic sales, partially offset by a weak international performance, led to an overall 47% increase in product revenues for Abiomed's first quarter of fiscal 2005. A rise in sales of its new AB5000 ventricles, AB5000 consoles and BVS blood pump accounted for the largest share of revenue growth. The Danvers, Massachusetts company also saw a 25% reduction in quarterly net loss compared with the same period last year.
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.